Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    Home»MedTech»CICC Initiates Coverage of Modern Dental Group (03600.HK) with Outperform Rating and Target Price of HK$10.0: Accelerating Global Expansion with Digital Efficiency
    MedTech

    CICC Initiates Coverage of Modern Dental Group (03600.HK) with Outperform Rating and Target Price of HK$10.0: Accelerating Global Expansion with Digital Efficiency

    Marie JonesBy Marie JonesOctober 12, 2026Updated:October 12, 2026No Comments2 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    CICC initiates coverage on Modern Dental Group (03600.HK) with an “Outperform” rating and a target price of HK$10.00, highlighting three key drivers. 1) Digitalization-led consolidation: intraoral scanning enables standardized cases to be processed centrally, supporting faster turnover and efficiency; the global market scale for dental prosthetics was ~US$24.3bn in 2025 with a low CR3 of 10.7%. 2) Global expansion through M&A: From IPO stage to 1H26, the company completed 15+ acquisitions, and Hexa Ceram contributed HK$216m revenue in 2025 (c. 60% of Group revenue growth). 3) Profit upside unlocked by centralized order and digital penetration: digital cases were ~35%–40% of volume in 2025, while digital cases processed at Asian production bases grew from 581k (2023) to 1.039m (2025) (CAGR ~33.7%) alongside a decline in staff cost ratio (48.0% to 43.6%), digital transformation is expected to drive profit growth ahead of revenue.

    CICC further notes that the rising penetration of intraoral scanning enables more cases to be captured locally, then transferred to Asian production bases for centralized design and production, creating a new window for efficiency gains in Modern Dental Group. CICC believes that there are multiple catalysts ahead: digital case volume growth beyond expectations, demand recovery in Europe, the US, and Southeast Asia exceeding expectations, and better-than-expected M&A integration alongside improved capacity utilization. CICC projects EPS of HK$0.83 (2026) and HK$1.07 (2027), implying a 29.3% CAGR for 2025–2027E. The current share price implies P/E of 9.6x (2026E) and 7.4x (2027E). CICC initiates an “Outperform” rating for the company with a target price of HK$10.0, based on a 2027E P/E of 9.3x, implying ~25.5% upside.

    Disclaimer: The views given in this article are extracted from relevant research report. For detailed information, please refer to the full report.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleMiami Fashion Week(R) Celebrates 10 Years With a Landmark Anniversary Edition, October 13-18, 2026
    Next Article Changzhou Microintelligence Co., Ltd passes HKEX Listing Committee hearing

    Related Posts

    CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China

    September 9, 2026

    CMS (867.HK/8A8.SG): Innovative Drug Lumirix(R) Approved in China for Additional Indication of Atopic Dermatitis (AD)

    September 4, 2026

    Cryofocus Announces 2026 Interim Results: Loss Narrows 37.9% to RMB 16.9 Million, Gross Margin Improves to 68.5%

    August 28, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Latest News

    • H3C CAS Named a Visionary in Gartner(R) Magic Quadrant(TM) for Server Virtualization Platforms
    • Autumn Electronics Fair and electronicAsia open today bringing global buyers to Hong Kong
    • Digi Power X Announces $200 Million Debt Financing Commitment to Support Completion of Alabama AI Data Center and Provides Expansion Update
    • ADK Group Enters into a Three-Year Strategic Business Partnership with Stagwell
    • Chervon Names Charlie Harte Director of Field Sales & Recruiting – Canada
    • Chervon Names Thomas G. Kentouris Vice President of Field Sales
    • Chervon Names Randall Durkan Vice President of Supply Chain – North America
    • Micot Pharma Debuts MT200605 Huntington’s Disease Research in a Poster Presentation at MDS 2026 and Expands Development into Neurodegenerative Diseases
    • Indonesia Urges Greater Transparency in Cross-Border Copyright Royalty Governance Before 35 Countries
    • Changzhou Microintelligence Co., Ltd passes HKEX Listing Committee hearing
    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.